The Rise of Psilocybin Use in the United States: A Multisource Observational Study
Annals of Internal Medicine April 21, 2025 Karilynn M Rockhill, Joshua C. Black, Michael S. Ladka et al. 29 citations
No Summary
Jennifer S. Jewell
5 papers in the library · 50 citations · publishing 2024-2025
Papers
Trends in poisonings involving ketamine in the United States, 2019-2023.
Drug and Alcohol Dependence March 1, 2025 Joseph J Palamar, Jennifer S. Jewell, Omar El-Shahawy et al. 9 citations
Reported ketamine poisonings in the US rose from 205 in 2019 to 414 in 2023, the highest in reporting history. Most cases involved ingestion (57.2%) and misuse or abuse (36.2%). The proportion of cases involving suspected suicide attempts doubled from 12.7% to 25.9%, and ingestion increased from 46.0% to 65.2%. Cases with major effects or death decreased from 23.4% to 15.6%. Overall, 18.6% of cases experienced a major event or death, but prevalence was lower for those who inhaled ketamine compared to those who did not. Both medical and recreational use and related adverse events need monitoring, especially as off-label prescribing of take-home oral formulations appears to be increasing.
Optimizing real-world benefit and risk of new psychedelic medications: the need for innovative postmarket surveillance
Nature Mental Health May 1, 2024 Joshua C. Black, Andrew A. Monte, Nabarun Dasgupta et al. 5 citations
As psychedelic-assisted psychotherapy nears FDA approval and broader use in the USA, current postmarket surveillance systems are ill-suited to monitor its real-world safety and effectiveness. Without a fit-for-purpose program, risks include misattributing adverse events to illicit psychedelics and failing to achieve equitable patient access. A successful surveillance mosaic should incorporate environmental, personal, and outcome domains to ensure safe, appropriate, and equitable care. The authors argue for intentionally designed data systems to proactively monitor utilization and inform reasonable limitations.
Psychedelic Trips: Travel Within the United States to Use Psychedelic Drugs After Legalization.
Annals of emergency medicine June 30, 2025 Joshua C. Black, Karilynn M Rockhill, Evelyn J Fox et al. 4 citations
About one-third of US adults who used psychedelics in the past year traveled out of state to do so, primarily to Colorado and Oregon, which have decriminalized natural psychedelics. Travelers were more likely than nontravelers to report anxiety or depression symptoms and to have visited an emergency department or urgent care for a psychedelic-related issue. They were also more likely to use psychedelics for medical symptoms, at healing centers, or at ceremonial sites. Emergency physicians in both legalized and nonlegal states should be aware that travel for psychedelic use is common and may carry risks of adverse outcomes.
Comparing Substance Use Consequences between Serotonergic Psychedelics, MDMA, and other Drugs of Abuse Among United States Adults with History of Psychiatric Illness
International Journal of Mental Health and Addiction April 1, 2025 Joshua C. Black, Nicole Schow, Hannah L. Burkett et al. 3 citations
Among US adults with a history of anxiety, major depression, PTSD, or bipolar disorder, past use of serotonergic psychedelics or MDMA is more common than in the general population—for example, 9.2% of those with bipolar disorder report such use versus 2.6% overall. Using a validated screening tool, psychedelic use was linked to higher scores indicating more severe substance use disorder risk, even after accounting for other drug use. However, the increase in risk was smaller than that associated with opioids or stimulants. The authors suggest that managing substance use disorder risks in psychedelic-assisted therapy may require different approaches than those used for other drugs.